Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

A new Duke study is exploring whether cells inside the nose could reveal early signs of Alzheimer’s disease. Researchers say ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

(WHTM) — A global campaign is marking Brain Awareness Week through Sunday, and Penn State professors are explaining some of ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Older people with a genetic risk of Alzheimer's disease did not experience the expected increase in cognitive decline and dementia risk if they consumed relatively large amounts of meat.